SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer (Q37131869)
Jump to navigation
Jump to search
scientific article published on 08 July 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer |
scientific article published on 08 July 2016 |
Statements
1 reference
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer (English)
1 reference
W E Barlow
D F Hayes
A F Schott
J R Gralow
W M Sikov
E A Perez
S Chennuru
H R Mirshahidi
S W Corso
D L Lew
L Pusztai
R B Livingston
8 July 2016
1 reference
1 reference
1 reference
1 reference
1 reference